A refined and translationally relevant model of chronic DSS colitis in BALB/c mice. (June 2018)

• Record Type: Journal Article
• Authors: Hoffmann, Maximilian; Schwertassek, Ulla; Seydel, Aleksandra; Weber, Klaus; Falk, Werner; Hauschildt, Sunna; Lehmann, Jörg
• Is Part Of: Laboratory animals. Volume 52:Number 3(2018)
• Page Start: 240
• Page End: 252
• Publication Date: 2018-06
• Subjects: IBD mouse model -- DSS colitis -- BALB/c mouse -- cyclosporine A -- 6-thioguanine; Animal experimentation -- Periodicals; Animal models in research -- Periodicals; Laboratory animals -- Periodicals; Animal welfare -- Periodicals; 636.0885
• DOI: 10.1177/0023677217742681
• Languages: English
• ISSNs: 0023-6772

Abstract

Inflammatory bowel diseases (IBD) are chronic relapsing disorders of the gastrointestinal tract. Several mouse models for IBD are available, but the acute dextran sulfate sodium (DSS)-induced colitis model is mostly used for preclinical studies. However, this model lacks chronicity and often leads to significant loss of mice. The aim of this study was to establish a refined and translationally relevant model of DSS chronic colitis in BALB/c mice. In the first part, we compared several standard therapeutic (ST) treatments for IBD in the acute DSS colitis model to identify the optimal treatment control for a DSS colitis model as compared to literature data. In the second part, we tested the two most effective ST treatments in a refined model of chronic DSS colitis. Cyclosporine A (CsA) and 6-thioguanine (6-TG) caused considerable reduction of clinical scores in acute DSS colitis. The clinical outcome was confirmed by the results for colon length and by histopathological evaluation. Moreover, CsA and 6-TG considerably reduced mRNA expression of several pro-inflammatory cytokines in spleen and colon. Both compounds also showed a substantial therapeutic effect in the refined model of chronic DSS colitis with regard to clinical scores and histopathology as well as the expression of inflammatory markers. The refined model of chronic DSS colitis reflects important features of IBD and is well suited to test potential IBD therapeutics.